Supernus Pharmaceuticals (SUPN) Non Operating Income (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Non Operating Income of $315000.0 for Q2 2026, down 93.04% year-over-year from $4.5 million in Q2 2025, and down 84.43% on a QoQ basis from $2.0 million in Q4 2025.
Supernus Pharmaceuticals (SUPN) Non Operating Income (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Non Operating Income for 16 years, with the latest figure at $315000.0 in Q2 2026.
- Non Operating Income for Q2 2026 came in at $315000.0, down 93.04% year-over-year; the trailing twelve-month figure through Jun 2026 was $9.1 million (down 49.28% YoY), and the FY2025 annual result was $13.3 million, down 18.21% from the prior year.
- Non Operating Income declined to $315000.0 in Q2 2026, from $2.0 million in the prior quarter.
- Over five years, Non Operating Income peaked at $12.8 million in Q1 2022 and troughed at -$22000.0 in Q2 2022.
- A 5-year average of $3.1 million and a median of $2.3 million in 2025 frame the typical range for Non Operating Income.
- The widest annual swing landed in 2023, when Non Operating Income soared 2190.91%; it then tumbled 93.04% in 2026.
- A 5-year view of Non Operating Income shows it stood at $806000.0 in 2022, then soared by 146.4% to $2.0 million in 2023, then soared by 150.6% to $5.0 million in 2024, then tumbled by 59.35% to $2.0 million in 2025, then tumbled by 84.43% to $315000.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were $315000.0 in Q2 2026, $2.0 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -224.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 5.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 41.90 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 10.70 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.76 Bn | 2.39 Bn | 185.39 Mn | 315,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 315,000.00 |
| Dec 31, 2025 | 2.02 Mn |
| Sep 30, 2025 | 2.28 Mn |
| Jun 30, 2025 | 4.53 Mn |
| Mar 31, 2025 | 4.43 Mn |
| Dec 31, 2024 | 4.98 Mn |
| Sep 30, 2024 | 4.10 Mn |
| Jun 30, 2024 | 3.73 Mn |
| Mar 31, 2024 | 3.40 Mn |
| Dec 31, 2023 | 1.99 Mn |
| Sep 30, 2023 | 1.75 Mn |
| Jun 30, 2023 | 460,000.00 |
| Mar 31, 2023 | 3.84 Mn |
| Dec 31, 2022 | 806,000.00 |
| Sep 30, 2022 | 1.08 Mn |
| Jun 30, 2022 | -22,000.00 |
| Mar 31, 2022 | 12.76 Mn |
| Sep 30, 2021 | -3.64 Mn |
| Jun 30, 2021 | -2.88 Mn |
| Mar 31, 2021 | -2.29 Mn |